Switching Parkinson’s patients to Crexont added more than three hours of daily symptom control in interim Phase 4 data. Here’s how to read an open-label, sponsor-run signal.

The American Academy of Sleep Medicine just clarified where combination therapy fits for chronic insomnia. Spoiler: CBT-I still wins, but pharmacotherapy alone has a narrower role.

The American Epilepsy Society released the first dedicated treatment guideline for infantile epilepsy. Two strong surgical recommendations sit alongside conditional pharmacological and dietary guidance.

The OSPREY trial puts proximal hypoglossal nerve stimulation on the map for moderate-to-severe OSA, with strong short-term numbers and the limitations a small unblinded RCT carries.

Brain endothelial cells exposed to a single sugar-free drink’s worth of erythritol shifted toward a pro-thrombotic state. Here’s how to talk about it without overstating the signal.

A 9-member Delphi panel just issued 65 implementation recommendations for anti-amyloid mAbs in private practice. Here’s what counts as practice-shaping and what’s still consensus opinion.